Altre lingue Neurotech International Limited

Azioni

NTI

AU000000NTI9

Mercato chiuso - Australian S.E. Altri mercati azionari 07:31:14 27/06/2024			Variaz. 5gg	Var. 1 gen.
0,072 ^AUD	-1,37%		+18,03%	+4,35%

06/06	L'attenuazione delle preoccupazioni sul rialzo dei tassi sostiene le azioni australiane	MT
06/06	Lo studio esteso sul farmaco NTI164 di Neurotech produce ulteriori miglioramenti; le azioni aumentano di quasi l'11%.	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Easing Rate Hike Concerns Shore Up Australian Shares	06/06
Neurotech's Extended NTI164 Drug Trial Yields Further Improvements; Shares Surge Nearly 11%	06/06
Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	17/04
Neurotech International Completes AU$10 Million Capital Raise	17/04
Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation	15/04
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	10/04
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	13/02
Neurotech's ASD Drug Trials Exceed 90 Weeks	07/02
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	29/01
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	19/12
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	04/12
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	14/11
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	13/11
Butterfly Network Announces 5-Year Co-Development Agreement with Forest Neurotech for Next-generation Brain Computer Interfaces Using Ultrasound-on-Chip Technology	25/10/23
Neurotech International Completes Enrollment for Rett Syndrome Trial	26/09/23
Alex Gorsky Joins Neurotech's Board as Lead Director	14/09/23
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	31/08/23
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	10/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Neurotech International Limited

Azioni

NTI

AU000000NTI9

Altre lingue

Filtri